Why Is Inspire (INSP) Up 7.5% Since Last Earnings Report?

Inspire Medical Systems (INSP) reported strong Q2 2025 results, with EPS of $0.45, up 40.6% year-over-year and exceeding consensus by 104.6%, and revenues of $217.1 million, up 10.8% and slightly above estimates. Despite this, the company significantly lowered its full-year 2025 revenue guidance to $900M-$910M (from $940M-$955M) and EPS guidance to $0.40-$0.50 (from $2.20-$2.30), citing factors like surgeon capacity constraints and GLP-1 medication trials. This substantial downward revision has driven consensus EPS estimates down by -118.76% and resulted in a Zacks Rank #5 (Strong Sell), contrasting with the stock's 7.5% gain since the last earnings report.

Analysis

Inspire Medical Systems (INSP) presents a conflicting picture where recent stock performance is decoupled from deteriorating forward-looking fundamentals. While the company reported a strong second-quarter 2025 earnings beat, with EPS up 40.6% year-over-year to $0.45, the underlying operational and financial trends are concerning. Revenue growth of 10.8% was offset by significant headwinds, including a 74 basis point contraction in gross margin, a 20.8% surge in SG&A expenses, and a swing from a $5.1 million operating profit in the prior-year quarter to a $3.3 million operating loss. The most critical development is the drastic reduction in full-year 2025 guidance; revenue projections were lowered from 17-19% growth to 12-13%, and EPS guidance was slashed from the $2.20-$2.30 range to just $0.40-$0.50. Management attributed this to surgeon capacity constraints and patient therapy delays related to trials of GLP-1 medications and the upcoming Inspire V launch. This severe guidance cut has prompted a -118.76% downward revision in consensus estimates and a Zacks Rank #5 (Strong Sell), indicating a deeply bearish analyst outlook that contradicts the stock's 7.5% price gain since the report.

Key Decisions for Investors

• Investors should be highly cautious of the severe downward revision in full-year EPS and revenue guidance, which signals significant operational headwinds and potential demand erosion from GLP-1 drugs.
• The recent 7.5% stock price appreciation appears fundamentally disconnected from the deteriorating forward outlook, margin contraction, and negative analyst revisions, suggesting the rally may be unsustainable.
• Given the Zacks Rank #5 (Strong Sell) and the magnitude of the guidance cut, it may be prudent to re-evaluate long positions, as the underlying data points to a high probability of a future pullback.
• Monitor future earnings calls closely for updates on surgeon capacity issues and the quantifiable impact of GLP-1 medications on patient demand, as these are the core drivers of the current negative outlook.